BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

99 related articles for article (PubMed ID: 7753547)

  • 81. Hypoxia induces p53 accumulation through MDM2 down-regulation and inhibition of E6-mediated degradation.
    Alarcón R; Koumenis C; Geyer RK; Maki CG; Giaccia AJ
    Cancer Res; 1999 Dec; 59(24):6046-51. PubMed ID: 10626788
    [TBL] [Abstract][Full Text] [Related]  

  • 82. Interaction of p53 with MDM2 is independent of E6 and does not mediate wild type transformation suppressor function.
    Marston NJ; Crook T; Vousden KH
    Oncogene; 1994 Sep; 9(9):2707-16. PubMed ID: 8058335
    [TBL] [Abstract][Full Text] [Related]  

  • 83. Differences in the ubiquitination of p53 by Mdm2 and the HPV protein E6.
    Camus S; Higgins M; Lane DP; Lain S
    FEBS Lett; 2003 Feb; 536(1-3):220-4. PubMed ID: 12586367
    [TBL] [Abstract][Full Text] [Related]  

  • 84. p53 in complex with DNA is resistant to ubiquitin-dependent proteolysis in the presence of HPV-16 E6.
    Molinari M; Milner J
    Oncogene; 1995 May; 10(9):1849-54. PubMed ID: 7753560
    [TBL] [Abstract][Full Text] [Related]  

  • 85. Multiple lysine mutations in the C-terminus of p53 make it resistant to degradation mediated by MDM2 but not by human papillomavirus E6 and induce growth inhibition in MDM2-overexpressing cells.
    Nakamura S; Roth JA; Mukhopadhyay T
    Oncogene; 2002 Apr; 21(16):2605-10. PubMed ID: 11971195
    [TBL] [Abstract][Full Text] [Related]  

  • 86. Oligomerisation of full length p53 contributes to the interaction with mdm2 but not HPV E6.
    Marston NJ; Jenkins JR; Vousden KH
    Oncogene; 1995 May; 10(9):1709-15. PubMed ID: 7753547
    [TBL] [Abstract][Full Text] [Related]  

  • 87. Intrasteric regulation of MDM2.
    Shimizu H; Hupp TR
    Trends Biochem Sci; 2003 Jul; 28(7):346-9. PubMed ID: 12877998
    [No Abstract]   [Full Text] [Related]  

  • 88. Covalent and noncovalent modifiers of the p53 protein.
    Jayaraman L; Prives C
    Cell Mol Life Sci; 1999 Jan; 55(1):76-87. PubMed ID: 10065153
    [TBL] [Abstract][Full Text] [Related]  

  • 89. Clinical implications of p53 alterations in oral cancer progression: a review from India.
    Patel KR; Vajaria BN; Singh RD; Begum R; Patel PS
    Exp Oncol; 2018 Mar; 40(1):10-18. PubMed ID: 29600984
    [TBL] [Abstract][Full Text] [Related]  

  • 90. The Basally Expressed p53-Mediated Homeostatic Function.
    Nagpal I; Yuan ZM
    Front Cell Dev Biol; 2021; 9():775312. PubMed ID: 34888311
    [TBL] [Abstract][Full Text] [Related]  

  • 91.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 92.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 93.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 94.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 95.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 96.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 97.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 98.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 99.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Previous]     [New Search]
    of 5.